Order RSDLImportant Safety Information

Tried.Tested.Trusted.

Reactive Skin Decontamination Lotion (RSDL®) Meets FDA Class I Requirements1

With chemical threats on the rise, an effective and reliable decontamination solution is essential.2,3

RSDL is a medical device designed to remove or neutralize chemical warfare agents and T-2 toxin from the skin.2,4

Learn More

When chemical warfare threatens

RSDL MEETS FDA CLASS I REQUIREMENTSAND COMBINES THE ABILITY TO1:

  • ACT

    WHEN EVERY SECOND COUNTS

    Presoaked sponge is ready for immediate use, and military-grade packaging is designed to withstand harsh operational environments.5-7

    See Usage Information

  • NEUTRALIZE

    CHEMICAL WARFARE AGENTS

    Decontamination is achieved through a combination of physical removal from the skin and rapid chemical neutralization.2

    Explore the MoA

  • DEFEND

    AGAINST MULTIPLE THREATS

    Across animal studies, RSDL demonstrated superior efficacy against nerve agents and a mustard agent when compared to water, bleach, and dry sorbents.8-10

    Review the Data

MAKING A DIFFERENCE WHEN THE THREAT IS REAL

  • 23

    Years of use by the US military4

  • 35+

    Countries with RSDL included in emergency stockpiles11

  • 20+

    Armed forces using RSDL around the world11,12

CHOOSE RSDL

The decontamination solution designed to safeguard responders when every second counts.2

Order RSDL

Important Safety Information

Intended Use

The RSDL® (Reactive Skin Decontamination Lotion) kit is intended to remove and/or neutralize chemical warfare agents (CWA) and T-2 toxin from the skin. For external use only by trained individuals. Use only if chemical warfare agent exposure is suspected.

CAUTION: Use only as directed. RSDL® is not a substitute for proper protective breathing devices and garments. Not for use prior to exposure (i.e., prophylactic use) or whole-body decontamination. Allow RSDL® to remain on the skin for at least two minutes. An RSDL® ingredient is absorbed through the skin which may cause adverse effects. Avoid leaving on the skin for long periods. Avoid contact with the eyes and mucous membranes and rinse eyes thoroughly if contact occurs. Remove RSDL® with soap and water when conditions permit. Keep out of reach of children.

WARNING: Fire Hazard. Combustion may occur upon contact with strong oxidizing chemicals (e.g., HTH [calcium hypochlorite], Super Tropical Bleach). Do not discard used RSDL® components into strong oxidizing chemicals or their containers.

The SAFETY Act (“the Act”) provides incentives for the development and deployment of anti-terrorism technologies by creating a system of “risk management” and a system of “litigation management.” The purpose of the Act is to ensure that the threat of liability does not deter potential manufacturers or Sellers of anti-terrorism technologies from developing, commercializing, and deploying technologies that could significantly reduce the risks or mitigate the effects of large-scale terrorist events. Thus, the Act creates certain liability limitations for “claims arising out of, relating to or resulting from an Act of Terrorism” where Qualified Anti-Terrorism Technologies have been deployed. The Act does not limit liability for harms caused by anti-terrorism technologies when no Act of Terrorism has occurred.

Suspected Adverse Events, Product Complaints & Medical Information:
serbmedinfo@serb.com / 877-377-3784

For more information on RSDL including order inquiries, please contact:
SERB MEDICAL SOLUTIONS INC. / 300 Four Falls Corporate Center, 300 Conshohocken State Road, Suite 300, West Conshohocken, PA 19428-3820
RSDL@serb.com

References
  1. Data on file. FDA Regulatory Analysis of Reactive Skin Decontamination Lotion Labeling Changes. November 2025. SERB Pharmaceuticals.
  2. Data on file. Reactive Skin Decontamination Lotion Kit. Clinical Evaluation Plan. March 2025. SERB Pharmaceuticals.
  3. Ciottone GR. Toxidome recognition in chemical-weapons attacks. N Engl J Med. 2018;378(17):1611-1620.
  4. Data on file. SERB Pharmaceuticals. Traditional 510(k) Premarket Notification. 2002.
  5. National Urban Security Technology Laboratory. Personal Decontamination Kits Market Survey Report. US Department of Homeland Security; 2017.
  6. Franken J, Mikler J. Reactive Skin Decontamination Lotion (RSDL) safety with clinical antiseptics and hemostatic agents. Toxicol Lett. 2024;395:11-16.
  7. Data on file, REF-3590. SERB Pharmaceuticals.
  8. Schwartz MD, Hurst CG, Kirk MA, Reedy SJD, Braue EH Jr. Reactive Skin Decontamination Lotion (RSDL) for the decontamination of chemical warfare agent (CWA) dermal exposure. Curr Pharm Biotechnol. 2012;13(10):1971-1979.
  9. Hanssen KA, Doxzon BF, Lumpkin HL, Clarkson E, Braue EH Jr. Evaluation of Decontamination Systems Challenged With Nerve Agents. US Army Medical Research Institute of Chemical Defense, US Department of War; 2006.
  10. Snider TH, Hayes TL, Jarvis RJ II, Matthews MC, Estep JE. A Medical Research and Evaluation Facility (MREF) and Studies Supporting the Medical Chemical Defense Program on Module 1 of Task 0008, Assessment of RSDL as a Decontaminant Against VX and HD: Efficacy, Equivalence to M291 Skin Decontamination Kit, and Compatibility with Fielded Materials. Battelle; 2001.
  11. Chemical Hazards Emergency Medical Management. Reactive Skin Decontamination Lotion (RSDL) - Medical Countermeasures Database. US Department of Health and Human Services. Accessed June 30, 2026. https://chemm.hhs.gov/countermeasure_RSDL.htm
  12. Data on file, REF-3589. SERB Pharmaceuticals.